JP5309014B2 - シナカルセットの多形体の製造および使用のための方法および組成物 - Google Patents
シナカルセットの多形体の製造および使用のための方法および組成物 Download PDFInfo
- Publication number
- JP5309014B2 JP5309014B2 JP2009501740A JP2009501740A JP5309014B2 JP 5309014 B2 JP5309014 B2 JP 5309014B2 JP 2009501740 A JP2009501740 A JP 2009501740A JP 2009501740 A JP2009501740 A JP 2009501740A JP 5309014 B2 JP5309014 B2 JP 5309014B2
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- cinacalcet
- form iii
- calcium
- crystalline polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78529406P | 2006-03-23 | 2006-03-23 | |
US60/785,294 | 2006-03-23 | ||
PCT/US2007/064700 WO2007112280A1 (fr) | 2006-03-23 | 2007-03-22 | Procédés et compositions pour la fabrication et l'utilisation de polymorphes du cinacalcet |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009531327A JP2009531327A (ja) | 2009-09-03 |
JP5309014B2 true JP5309014B2 (ja) | 2013-10-09 |
Family
ID=38328543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009501740A Expired - Fee Related JP5309014B2 (ja) | 2006-03-23 | 2007-03-22 | シナカルセットの多形体の製造および使用のための方法および組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8415501B2 (fr) |
EP (1) | EP2001832A1 (fr) |
JP (1) | JP5309014B2 (fr) |
AU (1) | AU2007230724B2 (fr) |
CA (1) | CA2645494C (fr) |
MX (1) | MX2008012061A (fr) |
WO (1) | WO2007112280A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090197970A1 (en) * | 2006-06-27 | 2009-08-06 | Sandoz Ag | Crystalline form of cinacalcet |
CA2657028A1 (fr) * | 2006-07-10 | 2008-01-17 | Indiana University Research And Technology Corporation | Methodes de traitement de maladies kystiques renales |
EP2114390A2 (fr) * | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Méthodes de traitement de troubles liés au podocyte |
CA2681582C (fr) | 2007-03-30 | 2015-07-14 | Amgen Inc. | Procedes de traitement de troubles intestinaux |
US20090137837A1 (en) | 2007-06-21 | 2009-05-28 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
JPWO2009119554A1 (ja) * | 2008-03-24 | 2011-07-21 | 味の素株式会社 | 消化管の重炭酸分泌促進剤 |
EP2300415A2 (fr) * | 2008-05-05 | 2011-03-30 | Medichem, S.A. | Procédé de contrôle de la dimension particulaire d'un dérivé de 3-ý(trifluorométhyl)phényl¨-1-aminopropane |
WO2010067204A1 (fr) | 2008-12-08 | 2010-06-17 | Actavis Group Ptc Ehf | Cinacalcet de pureté élevée ou l'un de ses sels de qualité pharmaceutique |
WO2010086129A1 (fr) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Complexe d'inclusion comprenant du cinacalcet et de la cyclodextrine |
US8759586B2 (en) | 2009-09-16 | 2014-06-24 | Ranbaxy Laboratories Limited | Processes for the preparation of cinacalcet |
US9205135B2 (en) | 2009-09-22 | 2015-12-08 | University Of Miami | Podocyte pH modulation and uses thereof |
EP2705842A1 (fr) * | 2012-09-05 | 2014-03-12 | Pharnext | Approches thérapeutiques pour le traitement de la maladie de Parkinson |
US20130085121A1 (en) * | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
EP2705843A1 (fr) * | 2012-09-05 | 2014-03-12 | Pharnext | Approches thérapeutiques pour le traitement de l'épilepsie et de troubles associés par réduction de l'épileptogenèse |
FR2995307A1 (fr) | 2012-09-07 | 2014-03-14 | Prod Chim Auxiliaires Et De Synthese | Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables |
WO2015136329A1 (fr) * | 2014-03-14 | 2015-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique de cinacalcet |
WO2016062278A1 (fr) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | Utilisation d'un médicament pour le traitement de maladies endocriniennes en vue de la préparation d'une composition pharmaceutique inhibant le cancer |
US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
KR101680464B1 (ko) | 2015-04-17 | 2016-11-28 | 가톨릭대학교 산학협력단 | 시나칼셋을 유효성분으로 함유하는 당뇨병성 미세혈관 합병증의 예방 및 치료용 약학적 조성물 |
DK3396380T3 (da) | 2017-04-27 | 2021-06-21 | Nipoka Gmbh | Diagnostisk værktøj til bestemmelse af udslettelse af podocytfodprocesser |
CN109200024A (zh) * | 2017-07-07 | 2019-01-15 | 江苏恒瑞医药股份有限公司 | 西那卡塞药物组合物及其医药用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0724561T3 (da) | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calciumreceptoraktive arylalkylaminer |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) * | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
ATE313321T1 (de) | 1991-08-23 | 2006-01-15 | Nps Pharma Inc | Kalzium-rezeptor aktive verbindungen |
DE69333527T2 (de) | 1993-02-23 | 2005-06-16 | Brigham & Women's Hospital, Inc., Boston | Calciumrezeptoraktive moleküle |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
DK1203761T3 (da) | 1994-12-08 | 2005-04-11 | Nps Pharma Inc | Calciumreceptoraktive forbindelser |
US5981599A (en) * | 1996-05-01 | 1999-11-09 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor active compounds |
EP0933354B1 (fr) * | 1996-07-08 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Composes actifs comme recepteurs du calcium |
TW483881B (en) * | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
AU760889B2 (en) * | 1998-10-14 | 2003-05-22 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-disubstituted cyclopropanes |
FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
US7176322B2 (en) * | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
PL3395338T3 (pl) * | 2003-09-12 | 2019-10-31 | Amgen Inc | Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl |
JP2008533170A (ja) * | 2005-03-17 | 2008-08-21 | アムジエン・インコーポレーテツド | 石灰化減少方法 |
EP1881954B1 (fr) * | 2005-05-16 | 2009-09-16 | Teva Pharmaceutical Industries Ltd. | Procede de preparation de chlorhydrate de cinacalcet |
EP1883625A2 (fr) | 2005-05-23 | 2008-02-06 | Teva Pharmaceutical Industries Ltd | Hydrochlorure de cinacalcet amorphe et sa preparation |
CA2605736A1 (fr) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Purification de cinacalcet |
ES2400693T3 (es) | 2005-09-02 | 2013-04-11 | Amgen Inc. | Regulación del equilibrio de fluido intestinal usando calcimiméticos |
KR20080055990A (ko) * | 2005-11-22 | 2008-06-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 시나칼셋 HCl의 결정형 및 이의 제조 방법 |
WO2007127445A2 (fr) | 2006-04-27 | 2007-11-08 | Teva Pharmaceutical Industries Ltd. | Procédé permettant de préparer une base de cinacalcet |
WO2007127449A1 (fr) | 2006-04-27 | 2007-11-08 | Teva Pharmaceutical Industries Ltd. | Procédé permettant de préparer une base de cinacalcet |
-
2007
- 2007-03-22 MX MX2008012061A patent/MX2008012061A/es active IP Right Grant
- 2007-03-22 AU AU2007230724A patent/AU2007230724B2/en not_active Ceased
- 2007-03-22 WO PCT/US2007/064700 patent/WO2007112280A1/fr active Application Filing
- 2007-03-22 EP EP07759176A patent/EP2001832A1/fr not_active Withdrawn
- 2007-03-22 JP JP2009501740A patent/JP5309014B2/ja not_active Expired - Fee Related
- 2007-03-22 CA CA2645494A patent/CA2645494C/fr not_active Expired - Fee Related
- 2007-03-22 US US11/690,036 patent/US8415501B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2645494C (fr) | 2016-01-12 |
JP2009531327A (ja) | 2009-09-03 |
EP2001832A1 (fr) | 2008-12-17 |
AU2007230724B2 (en) | 2014-01-30 |
US20070238790A1 (en) | 2007-10-11 |
MX2008012061A (es) | 2008-12-17 |
CA2645494A1 (fr) | 2007-10-04 |
WO2007112280A1 (fr) | 2007-10-04 |
US8415501B2 (en) | 2013-04-09 |
AU2007230724A1 (en) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5309014B2 (ja) | シナカルセットの多形体の製造および使用のための方法および組成物 | |
AU2017331345B2 (en) | Compounds and methods for IDO and TDO modulation, and indications therefor | |
CN106163516B (zh) | 异吲哚啉组合物和治疗神经变性疾病的方法 | |
TWI429435B (zh) | (2s,3r)-n-(2-((3-吡啶基)甲基)-1-氮雜雙環〔2.2.2〕辛-3-基)苯并呋喃-2-甲醯胺,其新穎鹽形式及使用方法 | |
JP7397011B2 (ja) | S1p1受容体に関連する状態を治療する方法 | |
US20210338669A1 (en) | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions | |
EP1988898A2 (fr) | Compositions pharmaceutiques pour le traitement du trouble d'hyperactivité avec déficit de l'attention | |
CN105008333B (zh) | N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 | |
CN103189358A (zh) | 5-ht2c激动剂的快速溶解剂型 | |
EA016904B1 (ru) | Новый холиновый сокристалл эпалрестата | |
CN103189359A (zh) | 5-ht2c激动剂的光学活性酸盐 | |
AU2004270238B2 (en) | Modafinil compositions | |
AU2017321016B2 (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
US20190224144A1 (en) | Method of treatment with anti-inflammatory and analgesic compounds which are gi-, renal-, and platelet-sparing | |
RU2578956C2 (ru) | Лекарственные формы, соли и полиморфы транснорсертралина и их применение | |
TW202334108A (zh) | 甲基酮及乙基酮 之同位素體、鹽、結晶形式、立體異構體及其使用方法 | |
KR20180014830A (ko) | 결정성 화합물 | |
CN104053436A (zh) | 用于治疗神经退行性疾病的组合物和方法 | |
TWI376373B (en) | Crystalline base of a pharmaceutical compound | |
US11958821B2 (en) | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | |
CN102918021B (zh) | 烟碱受体非竞争性拮抗剂 | |
JP5888612B2 (ja) | 縮合ピリジン化合物塩の結晶 | |
JP2023552908A (ja) | (5s)-シクロプロピル-5-[3-[(3s)-4-(3,5-ジフルオロフェニル)-3-メチル-ピペラジン-1-イル]-3-オキソ-プロピル]イミダゾリジン-2,4-ジオンの固体形態 | |
JP2007501254A (ja) | アセチルコリンエステラーゼ阻害特性を有する、シグマ‐1受容体配位子 | |
EP2042175A1 (fr) | Ligands du récepteur CB1 au traitement de l'obésité |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120711 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130701 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |